The Physiology of Human Brown Adipose Tissue
Beth Israel Deaconess Medical Center · with Joslin Diabetes Center, Chan Zuckerberg Initiative · NCT04352244
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- March 5, 2020
- Record last updated
- October 31, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Brown fat is a type of fat, found in both children and adults, which can produce heat and regulate the body's metabolism and energy use. White fat is the more common type of fat which is used to store extra calories. Understanding more about differences between brown and white fat may allow us to develop new approaches to improve the body's metabolism.
Being studied: Fat biopsy; Blood sampling; Blood sample for DNA analysis
Conditions: Adipose Tissue, Brown; Adipose Tissue; Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Healthy participants between age 18 and 75 years undergoing planned clinically indicated procedure at BIDMC.
Exclusion Criteria
- Body mass index (BMI) greater than or equal to 40 kg/m2
- History of any local or systemic infectious disease with fever or requiring antibiotic within four weeks of drug administration;
- Diabetes, either previously diagnosed or hemoglobin A1c greater than or equal to 6.5%
- Use of oral or parenteral corticosteroids (epidural permitted) or other medication known to cause insulin resistance in the previous 6 weeks.
- Willingness to provide informed consent and follow study procedures, including attending scheduled visits.
- Chronic kidney disease stage 4 or 5 (including end-stage renal disease);
- Hepatic disease, including serum alanine aminotransferase (ALT) or aspartate transaminase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin > 2.0;
- Active malignancy (except squamous or basal cell carcinoma of skin)
- Bleeding disorder, treatment with anticoagulants (if not discontinued prior to surgery), or platelet count \<50,000;
- Current addiction to alcohol or substances of abuse;
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation;
- Use of an investigational drug within 30 days prior to screening.
- There will be no involvement of special vulnerable populations such as fetuses, neonates, pregnant women, children, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.
- Because the goal is to study adult human brown adipose tissue, children are not eligible to participate.
Recruiting US locations
Beth Israel Deaconess Medical Center
Boston, MA 02215
Site contact: Andrew P White, MD · 6177549000 · apwhite@bidmc.harvard.edu
Study contacts (from the official record)
- Mary Elizabeth Patti, MD · 6173092635 · MaryElizabeth.Patti@joslin.harvard.edu
- Amanda L Sheehan, MSN · 6173092695 · amanda.sheehan@joslin.harvard.edu
Similar studies in Massachusetts
All weight loss studies in Massachusetts →- RecruitingHealthy volunteersOvernight stay mentioned
The Osteoarthritis Prevention Study
Wake Forest University
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 50+ · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Methuen, MA + 55 other US sites
- Eligibility basics
- Ages 18–79
- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Boston, MA + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Boston, MA + 43 other US sites
- Eligibility basics
- Ages 18+